Cryo-Cell International stock analysis
Want to see CCEL full AI Analyst Report?
Cryo-Cell International (CCEL) Stock Price & Analysis
CCEL Stock Chart & Stats
- Day’s Range
- $4.11 - $4.72
- 52-Week Range
- $2.72 - $5.45
- Previous Close
- $4.85
- Volume
- N/A
- Average Volume (3M)
- 12.24K
- Market Cap
- $36.69M
- Enterprise Value
- $38.46M
- Total Cash (Recent Filing)
- $4.23M
- Total Debt (Recent Filing)
- $577.20K
- Price to Earnings (P/E)
- ―
- Beta
- 0.13
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 21, 2025
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Positive Cash Generation
Positive operating and free cash flow provides internally generated funding for ongoing operations and customer service commitments. Its resilience despite reported net losses is a meaningful business strength, although sustaining this cash conversion will remain important for rebuilding financial flexibility.
Strong Gross Margin
A gross margin near 77% indicates that the core service offering retains substantial economics after direct costs. This creates potential to support laboratory operations, customer acquisition, and investment in the platform, provided operating expenses can be managed well enough to restore consistent profitability.
Recurring Storage Revenue Model
The combination of upfront processing revenue and recurring long-term storage fees can create durable customer relationships and a growing installed base of stored units. Retention and new enrollments therefore have the potential to compound revenue visibility beyond one-time birth-related transactions.
Bears Say
Deeply Negative Equity
Deeply negative equity leaves the company with a strained capital structure and reduces financial flexibility even though total debt has declined from earlier periods. The deficit reflects accumulated balance-sheet pressure and must be rebuilt before the company can operate with a more durable financial cushion.
Inconsistent Profitability
Current net losses weaken the company’s ability to fund growth and repair its balance sheet through retained earnings. The history of profitability recovering and then deteriorating again also indicates inconsistent earnings quality, making durable margins and dependable long-term earnings power less established.
Stagnant Revenue Trend
Flat to declining revenue suggests that customer enrollment, pricing, retention, or related service growth is not currently expanding the business meaningfully. Without renewed top-line growth, the company has less operating leverage to absorb costs, improve earnings, and generate the resources needed to strengthen its finances.
CCEL FAQ
What was Cryo-Cell International’s price range in the past 12 months?
What is Cryo-Cell International’s market cap?
When is Cryo-Cell International’s upcoming earnings report date?
How were Cryo-Cell International’s earnings last quarter?
Is Cryo-Cell International overvalued?
Does Cryo-Cell International pay dividends?
What is Cryo-Cell International’s EPS estimate?
How many shares outstanding does Cryo-Cell International have?
What happened to Cryo-Cell International’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cryo-Cell International?
What is the TipRanks Smart Score and how is it calculated?
Cryo-Cell International Stock Smart Score
Company Description
Cryo-Cell International
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- David Portnoy
- Employees
- 74
- Website
- www.cryo-cell.com
- Address
- 700 Brooker Creek Boulevard, Oldsmar, FL, 34677, US
Cryo-Cell International (CCEL) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 4 | 9 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 5 | 0 | 7 |












